The FDA accepted Novartis' application to sell a knockoff of Amgen's biological treatment Neupogen, making the company a pioneer among those looking to capitalize on a soon-to-come U.S. market for biosimilars that is expected to explode.
Welcome to the latest edition of our weekly EuroBiotech Report. This week the United Kingdom government underlined the importance it places on life sciences--and the jobs it brings--by creating a position dedicated to the industry. George Freeman, the former biotech venture capitalist who has shaped the government's life sciences strategy, has filled the position. Part of Freeman's brief is to support the British biotech industry, a sector Neil Woodford has been credited with helping through some tough times. Woodford has maintained an interest in biotechs at his new fund, with 11 small drug developers sitting alongside a who's who of European Big Pharma in his portfolio. Biotechs in two of Britain's neighbors received good news, with France's Genfit being boosted by a bullish analyst report and Dutch biotech Pharming ending a roller-coaster week with an FDA approval. The CEO of an Italian drug developer spoke of the difficulty of doing business in his home country and why it drove him to list the company in Switzerland, not Milan. And more. Read this week's full EuroBiotech Report >>
Our annual top women in biotech report spotlights women in the life sciences industry, academia and regulatory roles who are outstanding members of the field. Our nomination form for this year's report is now open and I'd like to encourage you to submit your nominations below or click here. The deadline for nominations is September 1.
Like we always do about this time of year, FierceBiotech is kicking off its search for the next class of Fierce 15 companies, and we want to hear from you. It's easy: Just fill out the form embedded below or find it here.
We're looking for the brightest and bravest among private biotechs, and reader nominations complement our research, interviews and debates in assembling the list each year. Take this opportunity to chime in and tell us what makes your nominee worthy of the Fierce 15.
POPULAR COMMENT THREADS
A pair of Asian pharma companies is bankrolling a rare operation: a brand new VC organization--Remiges Ventures--that plans to go hunting for biotech startups in the U.S. and Europe. Read more >>
Over the last few years there's been something of a shakeout among biotech venture investors. There are fewer big players, but with IPOs taking flight again, established venture groups are rolling out new funds collectively worth billions of dollars. And now a pair of Asian pharma companies is bankrolling a rare operation: a brand new VC organization--Remiges Ventures--that plans to go hunting for biotech startups in the U.S. and Europe.
Six biotechs were expected to go public this week, eyeing nearly $400 million combined, but that potential has so far amounted to one deeply discounted offering, one bottom-of-the-range debut and one outright cancelation.
Israeli drug developer Atox Bio has raised a $23 million E round to support its treatment for rare, tissue-destroying bacteria, paving the way for late-stage work.
Gilead said today that the FDA has approved its PI3k inhibitor idelalisib for three types of B-cell blood cancers following its early Phase III success last fall on impressive leukemia data. EvaluatePharma analysts estimate this drug could earn $1.2 billion a year by 2020, making it one of the top therapies in late-stage development.
From Our Sister Sites
Varian Medical Systems closed out a winning streak, while AngioDynamics deepened its losses when each company reported earnings for the second quarter.
Bristol-Myers Squibb's melanoma drug Yervoy and clot-fighter Eliquis helped boost its earnings past analyst forecasts, with $333 million in profits on $3.9 billion in revenue.